Pliant Therapeutics Inc (NASDAQ: PLRX) kicked off on Monday, down -3.55% from the previous trading day, before settling in for the closing price of $15.20. Over the past 52 weeks, PLRX has traded in a range of $10.22-$19.62.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales slid by -32.88% over the last five years. While this was happening, its average annual earnings per share was recorded -32.88%. With a float of $53.70 million, this company’s outstanding shares have now reached $59.92 million.
The firm has a total of 158 workers. Let’s measure their productivity. In terms of profitability, gross margin is 45.37%, operating margin of -4292.42%, and the pretax margin is -3830.68%.
Pliant Therapeutics Inc (PLRX) Insider Activity
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Pliant Therapeutics Inc is 11.68%, while institutional ownership is 101.88%. The most recent insider transaction that took place on Jul 10 ’24, was worth 142,408. In this transaction Chief Medical Officer of this company sold 12,319 shares at a rate of $11.56, taking the stock ownership to the 213,052 shares. Before that another transaction happened on Jul 10 ’24, when Company’s Chief Business Officer sold 9,900 for $11.56, making the entire transaction worth $114,444. This insider now owns 227,494 shares in total.
Pliant Therapeutics Inc (PLRX) Earnings and Forecasts
In the latest quarterly report, which was put into the public domain on 6/30/2024, the organization reported -0.7 earnings per share (EPS), higher than consensus estimate (set at -0.77) by 0.07. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.99 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -32.88% per share during the next fiscal year.
Pliant Therapeutics Inc (NASDAQ: PLRX) Trading Performance Indicators
Take a look at Pliant Therapeutics Inc’s (PLRX) current performance indicators. Last quarter, stock had a quick ratio of 14.47.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.09, a number that is poised to hit -0.97 in the next quarter and is forecasted to reach -4.03 in one year’s time.
Technical Analysis of Pliant Therapeutics Inc (PLRX)
Analysing the last 5-days average volume posted by the [Pliant Therapeutics Inc, PLRX], we can find that recorded value of 0.5 million was better than the volume posted last year of 0.46 million. As of the previous 9 days, the stock’s Stochastic %D was 88.65%. Additionally, its Average True Range was 0.80.
During the past 100 days, Pliant Therapeutics Inc’s (PLRX) raw stochastic average was set at 86.38%, which indicates a significant increase from 86.38% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 76.03% in the past 14 days, which was higher than the 57.58% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $12.56, while its 200-day Moving Average is $13.77. Now, the first resistance to watch is $15.12. This is followed by the second major resistance level at $15.58. The third major resistance level sits at $15.98. If the price goes on to break the first support level at $14.26, it is likely to go to the next support level at $13.86. Should the price break the second support level, the third support level stands at $13.40.
Pliant Therapeutics Inc (NASDAQ: PLRX) Key Stats
The company with the Market Capitalisation of 891.33 million has total of 60,326K Shares Outstanding. Its annual sales at the moment are 1,580 K in contrast with the sum of -161,340 K annual income. Company’s last quarter sales were recorded 0 K and last quarter income was -55,850 K.
